Prospective non controlled study of immunogenicity of Human Papilloma Virus (HPV) Vaccine in groups at special risk of poor vaccine result.
Phase of Trial: Phase III
Latest Information Update: 08 Jun 2016
At a glance
- Drugs Human papillomavirus vaccine recombinant quadrivalent Merck (Primary)
- Indications Cervical cancer; Human papillomavirus infections
- Focus Pharmacodynamics
- 17 Apr 2011 Status changed from recruiting to completed, according to ClinicalTrials.gov record.
- 25 Aug 2009 Additional lead trial centres and investigators identified as reported by ClinicalTrials.gov.
- 25 Aug 2009 New source identified and integrated (ClinicalTrials.gov record).